This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life.
The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth.
Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study.
The study will look at data already existing in the participants' medical charts.
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.
CDK4/6 inhibitors are currently the standard treatment for female breast cancer patients with HR+ tumors. However, there is no established standard treatment for patients who experience treatment failure with CDK4/6 inhibitors. The MAINTAIN study has shown clinical benefits by switching to Ribociclib and changing endocrine therapy after progression on CDK4/6 inhibitors. We hypothesize that combining Dalpiciclib with physician-selected endocrine therapy, following treatment failure with CDK4/6 inhibitors, would similarly lead to improved patient survival. In this study, 18F-FES PET/CT will be employed as a non-invasive alternative to biopsy techniques for evaluating the expression of ER in various systemic lesions of the patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
•Wyniki badań wykazały, że rak piersi ma cechy HR-dodatnie i HER2-ujemne.
•Specjalistyczne badanie obrazowe (PET/CT z 18F-FES) potwierdziło obecność komórek nowotworowych reagujących na hormony.
•Ogólny stan zdrowia pacjentki pozwala na udział w badaniu (oceniane według skali ECOG).
•Przewidywany czas życia pacjentki wynosi co najmniej 3 miesiące.
•Pacjentka wcześniej otrzymywała określone leczenie, w tym terapie celowane (inhibitory CDK4/6) oraz chemioterapię lub leczenie hormonalne.
•Pacjentka wyraża zgodę na wykonanie standardowego badania PET/CT z 18F-FDG.
•Wykryto co najmniej jedną zmianę nowotworową poza czaszką, którą można zmierzyć.
•Funkcje ważnych organów pacjentki są w normie i pacjentka wyzdrowiała z ewentualnych skutków ubocznych poprzedniego leczenia.
✗ Disqualifies
•Badanie PET/CT z 18F-FES wykazało, że wszystkie komórki nowotworowe nie reagują na hormony.
•Pacjentka wcześniej przyjmowała lek Dalpiciclib.
•Potwierdzono przerzuty do opon mózgowo-rdzeniowych lub do mózgu.
•Pacjentka jest w stanie krytycznym, szybko postępuje choroba lub nie nadaje się do leczenia hormonalnego.
•Pacjentka ma wodobrzusze, objawowy płyn w jamie opłucnej lub osierdziu, który wymaga drenażu.
•Pacjentka ma trudności z połykaniem, niedrożność jelit lub inne problemy wpływające na przyjmowanie leków.
•Pacjentka chorowała na inne nowotwory w ciągu ostatnich 5 lat (z pewnymi wyjątkami dotyczącymi raka skóry).
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
Your privacy
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy